Based on findings from the FLAURA study, osimertinib is recommended as a first-line treatment for patients with advanced NSCLC presenting with activating EGFR mutations, irrespective of their T790M status [16, 17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.